Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Neurology
Published in: BMC Neurology 1/2018

Open Access 01-12-2018 | Research article

Comparison of the perioperative time courses of matrix metalloproteinase-9 (MMP-9) and its inhibitor (TIMP-1) during carotid artery stenting (CAS) and carotid endarterectomy (CEA)

Authors: Ákos Mérei, Bálint Nagy, Gábor Woth, János Lantos, Ferenc Kövér, Lajos Bogár, Diána Mühl

Published in: BMC Neurology | Issue 1/2018

Login to get access

Abstract

Background

Our aim was to compare the perioperative time courses of matrix metalloproteinase-9 (MMP-9) and its inhibitor (TIMP-1) in during carotid endarterectomy (CEA) and carotid artery stenting (CAS).

Methods

In our prospective study, twenty-five patients who were scheduled to undergo CAS were enrolled. We used a matched, historical CEA group as controls. Blood samples were collected at four time points: T1: preoperative; T2: 60 min after stent insertion; T3: first postoperative morning; and T4: third postoperative morning. Plasma MMP-9 and TIMP-1 levels were measured by ELISA.

Results

In the CEA group, the plasma levels of MMP-9 were significantly elevated at T3 compared to T1. In the CAS group, there was no significant difference in MMP-9 levels in the perioperative period. MMP-9 levels were significantly higher in the T3 samples of the CEA group compared to the CAS group. Significantly lower TIMP-1 levels were measured in both groups at T2 than at T1 in both groups. MMP-9/TIMP-1 at T3 was significantly higher than that at T1 in the CEA group compared to both T1 and the CAS group.

Conclusions

CAS triggers smaller changes in the MMP-9-TIMP-1 system during the perioperative period, which may correlate with a lower incidence of central nervous system complications. Additional studies as well as cognitive and functional surveys are warranted to determine the clinical relevance of our findings.

Trial registration

NIH U.S. National Library of Medicine, Clinicaltrials.gov,NCT03410576, 24.01.2018, Retrospectively registered
Literature
1.
Zorowitz RD, Chen E, Bianchini Tong K, Laouri M. Costs and rehabilitation use of stroke survivors: a retrospective study of Medicare beneficiaries. Top Stroke Rehabil. 2009;16:309–20.CrossRefPubMed
2.
Soler EP, Ruiz VC. Epidemiology and risk factors of cerebral ischemia and ischemic heart diseases: similarities and differences. Curr Cardiol Rev. 2010;6:138–49.CrossRefPubMedPubMedCentral
3.
Dickerson LM, Carek PJ, Quattlebaum RG. Prevention of recurrent ischemic stroke. Am Fam Physician. 2007;76:382–8.PubMed
4.
Liapis CD, Bell PRF, Mikhailidis D, Sivenius J, Nicolaides A, Fernandes e Fernandes J, et al. ESVS guidelines. Invasive treatment for carotid stenosis: indications, techniques. Eur J Vasc Endovasc Surg. 2009;37:1–19.CrossRefPubMed
5.
Yip H-K, Sung P-H, Wu C-J, Yu C-M. Carotid stenting and endarterectomy. Int J Cardiol. 2016;214:166–74.CrossRefPubMed
6.
Featherstone RL, Dobson J, Ederle J, Doig D, Bonati LH, Morris S, et al. Carotid artery stenting compared with endarterectomy in patients with symptomatic carotid stenosis (international carotid stenting study): a randomised controlled trial with cost-effectiveness analysis. Health Technol Assess. 2016;20:1–94.CrossRefPubMedPubMedCentral
7.
Meier P, Knapp G, Tamhane U, Chaturvedi S, Gurm HS. Short term and intermediate term comparison of endarterectomy versus stenting for carotid artery stenosis: systematic review and meta-analysis of randomised controlled clinical trials. BMJ. 2010;340:c467.CrossRefPubMedPubMedCentral
8.
Meller SM, Salim Al-Damluji M, Gutierrez A, Stilp E, Mena-Hurtado C. Carotid stenting versus endarterectomy for the treatment of carotid artery stenosis: contemporary results from a large single center study. Catheter Cardiovasc Interv. 2016;88(5):822–30.CrossRefPubMed
9.
Bonati LH, Ederle J, McCabe DJH, Dobson J, Featherstone RL, Gaines PA, et al. Long-term risk of carotid restenosis in patients randomly assigned to endovascular treatment or endarterectomy in the carotid and vertebral artery transluminal angioplasty study (CAVATAS): long-term follow-up of a randomised trial. Lancet Neurol. 2009;8:908–17.CrossRefPubMedPubMedCentral
10.
SPACE Collaborative Group, Ringleb PA, Allenberg J, Brückmann H, Eckstein H-H, Fraedrich G, et al. Thirty day results from the SPACE trial of stent-protected angioplasty versus carotid endarterectomy in symptomatic patients: a randomised non-inferiority trial. Lancet. 2006;368:1239–47.CrossRef
11.
Bonati LH, Ederle J, Dobson J, Engelter S, Featherstone RL, Gaines PA, et al. Length of carotid stenosis predicts peri-procedural stroke or death and restenosis in patients randomized to endovascular treatment or endarterectomy. Int J Stroke. 2014;9:297–305.CrossRefPubMed
12.
Choi JC, Johnston SC, Kim AS. Early outcomes after carotid artery stenting compared with endarterectomy for asymptomatic carotid stenosis. Stroke. 2015;46:120–5.CrossRefPubMed
13.
Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke. 2014;45:2160–236.CrossRefPubMed
14.
Li J, Wang Y. Blood biomarkers in minor stroke and transient ischemic attack. Neurosci Bull. 2016:1–6.
15.
Ramos-Fernandez M, Bellolio MF, Stead LG. Matrix Metalloproteinase-9 as a marker for acute ischemic stroke: a systematic review. J Stroke Cerebrovasc Dis. 2011;20:47–54.CrossRefPubMed
16.
Molloy K, Thompson M, Schwalbe E, Bell PR, Naylor A, Loftus I. Elevation in plasma MMP-9 following carotid endarterectomy is associated with particulate cerebral embolisation. Eur J Vasc Endovasc Surg. 2004;27:409–13.CrossRefPubMed
17.
Lorente L, Martín MM, Labarta L, Díaz C, Solé-Violán J, Blanquer J, et al. Matrix metalloproteinase-9, −10, and tissue inhibitor of matrix metalloproteinases-1 blood levels as biomarkers of severity and mortality in sepsis. Crit Care. 2009;13:R158.CrossRefPubMedPubMedCentral
18.
Mühl D, Nagy B, Woth G, Falusi B, Bogár L, Weber G, et al. Dynamic changes of matrix metalloproteinases and their tissue inhibitors in severe sepsis. J Crit Care. 2011;26:550–5.CrossRefPubMed
19.
Mühl D, Ghosh S, Uzuelli JA, Lantos J, Tanus-Santos JE. Increases in circulating matrix metalloproteinase-9 levels following fibrinolysis for acute pulmonary embolism. Thromb Res. 2010;125:549–53.CrossRefPubMed
20.
Chaturvedi M, Kaczmarek L. Mmp-9 inhibition: a therapeutic strategy in ischemic stroke. Mol Neurobiol. 2014;49:563–73.CrossRefPubMed
21.
Crocker SJ, Pagenstecher A, Campbell IL. The TIMPs tango with MMPs and more in the central nervous system. J Neurosci Res. 2004;75:1–11.CrossRefPubMed
22.
Nagy B, Woth G, Mérei Á, Nagy L, Lantos J, Menyhei G, et al. Perioperative time course of matrix metalloproteinase-9 (MMP-9), its tissue inhibitor TIMP-1 & S100B protein in carotid surgery. Indian J Med Res. 2016;143:220–6.CrossRefPubMedPubMedCentral
23.
Giuliani E, Genedani S, Moratto R, Veronesi J, Carone C, Bonvecchio C, et al. Neural damage biomarkers during open carotid surgery versus endovascular approach. Ann Vasc Surg. 2014;28:1671–9.CrossRefPubMed
24.
Gaudet JG, Yocum GT, Lee SS, Granat A, Mikami M, Connolly ES, et al. MMP-9 levels in elderly patients with cognitive dysfunction after carotid surgery. J Clin Neurosci. 2010;17:436–40.CrossRefPubMedPubMedCentral
25.
Tayebjee MH, Lip GYH, Blann AD, MacFadyen RJ. Effects of age, gender, ethnicity, diurnal variation and exercise on circulating levels of matrix metalloproteinases (MMP)-2 and −9, and their inhibitors, tissue inhibitors of matrix metalloproteinases (TIMP)-1 and −2. Thromb Res. 2005;115:205–10.CrossRefPubMed
26.
Marchesi C, Dentali F, Nicolini E, Maresca AM, Tayebjee MH, Franz M, et al. Plasma levels of matrix metalloproteinases and their inhibitors in hypertension. J Hypertens. 2012;30:3–16.CrossRefPubMed
27.
Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and Atherogenesis. Circ Res. 2002;90(3):251–62.PubMedCrossRef
28.
Niemirska A, Litwin M, Trojanek J, Gackowska L, Kubiszewska I, Wierzbicka A, et al. Altered matrix metalloproteinase 9 and tissue inhibitor of metalloproteinases 1 levels in children with primary hypertension. J Hypertens. 2016;34:1815–22.CrossRefPubMed
29.
Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, Hafner G, et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation. 2003;107(12):1579–85.CrossRefPubMed
30.
Marx N, Froehlich J, Siam L, Ittner J, Wierse G, Schmidt A, et al. Antidiabetic PPARγ-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arterioscler Thromb Vasc Biol. 2003;23(2):283–8.CrossRefPubMed
31.
Schuyler CA, Ta NN, Li Y, Lopes-Virella MF, Huang Y. Insulin treatment attenuates diabetes-increased atherosclerotic intimal lesions and matrix metalloproteinase 9 expression in apolipoprotein E-deficient mice. J Endocrinol. 2011;210:37–46.CrossRefPubMed
32.
Wesley UV, Bove PF, Hristova M, McCarthy S, van der Vliet A. Airway epithelial cell migration and wound repair by ATP-mediated activation of dual oxidase 1. J Biol Chem. 2007;282:3213–20.CrossRefPubMed
33.
Huwiler A, Akool e-S, Aschrafi A, Hamada FMA, Pfeilschifter J, Eberhardt W. ATP potentiates interleukin-1 beta-induced MMP-9 expression in mesangial cells via recruitment of the ELAV protein HuR. J Biol Chem. 2003;278(51):51758–69.CrossRefPubMed
34.
Choi MS, Cho KS, Shin SM, Ko HM, Kwon KJ, Shin CY, et al. ATP induced microglial cell migration through non-transcriptional activation of matrix Metalloproteinase-9. Arch Pharm Res. 2010;33:257–65.CrossRefPubMed
35.
Sternberg Z, Chichelli T, Sternberg D, Sawyer R, Ching M, Janicke D, et al. Relationship between inflammation and aspirin and Clopidogrel antiplatelet responses in acute ischemic stroke. J Stroke Cerebrovasc Dis. 2016;25:327–34.CrossRefPubMed
36.
Santos-Martínez MJ, Medina C, Jurasz P, Radomski MW. Role of metalloproteinases in platelet function. Thromb Res. 2008;121:535–42.CrossRefPubMed
37.
Montaner J, Alvarez-Sabín J, Molina C, Anglés A, Abilleira S, Arenillas J, et al. Matrix metalloproteinase expression after human Cardioembolic stroke. Stroke. 2001;32(8):1759–66.CrossRefPubMed
38.
Zhao B-Q, Wang S, Kim H-Y, Storrie H, Rosen BR, Mooney DJ, et al. Role of matrix metalloproteinases in delayed cortical responses after stroke. Nat Med. 2006;12:441–5.CrossRefPubMed
39.
Tedesco MM, Lee JT, Dalman RL, Lane B, Loh C, Haukoos JS, et al. Postprocedural microembolic events following carotid surgery and carotid angioplasty and stenting. J Vasc Surg. 2007;46:244–50.CrossRefPubMed
40.
Montorsi P, Caputi L, Galli S, Ciceri E, Ballerini G, Agrifoglio M, et al. Microembolization during carotid artery stenting in patients with high-risk, lipid-rich plaque: a randomized trial of proximal versus distal cerebral protection. J Am Coll Cardiol. 2011;58:1656–63.CrossRefPubMed
41.
Agren MS, Jorgensen IN, Andersen M, Viljanto J, Gottrup P. Matrix metalloproteinase 9 level predicts optimal collagen deposition during early wound repair in humans. Br J Surg. 1998;85:68–71.CrossRefPubMed
Metadata
Title
Comparison of the perioperative time courses of matrix metalloproteinase-9 (MMP-9) and its inhibitor (TIMP-1) during carotid artery stenting (CAS) and carotid endarterectomy (CEA)
Authors
Ákos Mérei
Bálint Nagy
Gábor Woth
János Lantos
Ferenc Kövér
Lajos Bogár
Diána Mühl
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Neurology / Issue 1/2018
Electronic ISSN: 1471-2377
DOI
https://doi.org/10.1186/s12883-018-1133-1

Other articles of this Issue 1/2018

BMC Neurology 1/2018 Go to the issue

Research article

Predictive value of early magnetic resonance imaging measures is differentially affected by the dose of interferon beta-1a given subcutaneously three times a week: an exploratory analysis of the PRISMS study

Research article

Neurological signs as early determinants of dementia and predictors of mortality among older adults in Latin America: a 10/66 study using the NEUROEX assessment

Research article

A retrospective case series of segmental zoster paresis of limbs: clinical, electrophysiological and imaging characteristics

Case report

Basal ganglia hemorrhage in a case report following spinal surgery

Research article

Results of a randomized, double blind, placebo controlled, crossover trial of melatonin for treatment of Nocturia in adults with multiple sclerosis (MeNiMS)

Research article

Hyperuricemia and dementia – a case-control study